JNJ-8114 / J&J - LARVOL DELTA

A phase 1, first-in-human, dose escalation study of JNJ-80038114, a PSMAxCD3 bispecific antibody, in participants with metastatic castration-resistant prostate cancer. (PubMed, Cancer Chemother Pharmacol) - P1 | "This first-in-human study of JNJ-80038114 was discontinued early due to its lack of preliminary clinical activity, neurologic toxicities, high rates of CRS, and the development of ADAs impacting PK."

Clinical • First-in-human • Journal • P1 data • Castration-Resistant Prostate Cancer • Fatigue • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

A Study of JNJ-80038114 in Participants With Advanced Stage Prostate Cancer (clinicaltrials.gov) - P1 | N=39 | Completed | Sponsor: Janssen Research & Development, LLC | Recruiting ➔ Completed | N=90 ➔ 39 | Trial completion date: Mar 2025 ➔ Mar 2024 | Trial primary completion date: Mar 2025 ➔ Mar 2024

Enrollment change • Metastases • Trial completion • Trial completion date • Trial primary completion date • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

A Study of JNJ-80038114 in Participants With Advanced Stage Prostate Cancer (clinicaltrials.gov) - P1 | N=90 | Recruiting | Sponsor: Janssen Research & Development, LLC | Trial completion date: Jun 2025 ➔ Mar 2025

Metastases • Trial completion date • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

A Study of JNJ-80038114 in Participants With Advanced Stage Prostate Cancer (clinicaltrials.gov) - P1 | N=110 | Recruiting | Sponsor: Janssen Research & Development, LLC | Not yet recruiting ➔ Recruiting | Trial completion date: Mar 2025 ➔ Jun 2025

Enrollment open • Trial completion date • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

A Study of JNJ-80038114 in Participants With Advanced Stage Prostate Cancer (clinicaltrials.gov) - P1 | N=110 | Not yet recruiting | Sponsor: Janssen Research & Development, LLC

New P1 trial • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor